enGene Holdings Inc. Hits Significant Milestones with Q3 2025 Financials and Strategic AdvancesIn a notable stride towards therapeutic innovation, enGene Holdings Inc. (Nasdaq: ENGN), a clinical-stage, non-viral gene therapy company, has released its financial results for the third quarter ended July 31, 2025. Alongside these results, the company has shared promising business updates that highlight enGene s commitment to advancing its ambitious therapeutic pipeline.Ron Cooper, Chief Executive Officer of enGene, underscored significant breakthroughs in the company s development strategy, expressing a forward-looking confidence. Reaching target enrollment in LEGEND s pivotal Cohort 1 and securing RMAT (Regene...
Breakthrough in Bladder Cancer Treatment: enGene Achieves Key Milestone in Phase 2 LEGEND Trial enGene Holdings Inc. Reaches Target Enrollment in Pivotal Cohort for High-Risk NMIBC Trial BOSTON and MONTREAL enGene Holdings Inc. (Nasdaq: ENGN, enGene or the Company), a pioneering clinical-stage, non-viral gene therapy company, has announced a landmark achievement in its mission to transform the treatment landscape for patients with high-risk, non-muscle invasive bladder cancer (NMIBC). The company successfully reached its target enrollment milestone, gathering 100 patients for the pivotal cohort of its ongoing, open-label, multi-cohort Phase 2 LEGEND trial of detalimogene voraplasmid (formerly known as EG-70...
A Pivotal Period for enGeneBOSTON and MONTREAL enGene Holdings Inc. (Nasdaq: ENGN), a clinical-stage genetic medicines company, has recently unveiled its financial results for the third quarter of 2024, alongside a significant business update. The company continues to make strides in molecular therapeutics, particularly with its lead investigational product, detalimogene voraplasmid (commonly referred to as detalimogene, and previously known as EG-70). This cutting-edge genetic therapy is currently being evaluated in a pivotal study involving patients suffering from high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis). Financial Over...
Boston and Montreal-based enGene Holdings Inc. (Nasdaq: ENGN), a genetic medicines company specializing in non-viral, intravesical treatments, has released its financial results for the second quarter ended April 30, 2024. The company s lead candidate, EG-70, is currently undergoing a pivotal study for high-risk non-muscle invasive bladder cancer (NMIBC) that is unresponsive to Bacillus Calmette-Guérin (BCG) treatment.enGene Holdings Inc. appreciates the successful completion of its $200 million private placement in February. The company believes the investment will facilitate the execution of its strategic s. This funding has contributed significantly to the firm s progress in clinical trials and overall b...
Sources:
Engene Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Engene Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Engene Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
